Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma.
Kinoshita R, Ishibashi M, Handa H, Sasaki M, Imai Y, Tanaka N, Ito S, Sunakawa-Kii M, Kaito Y, Asayama T, Komatsu N, Tanaka J, Odajima T, Sugimori H, Yamaguchi H, Inokuchi K, Tamura H. Kinoshita R, et al. Among authors: imai y. Exp Hematol. 2023 May;121:38-47.e2. doi: 10.1016/j.exphem.2023.01.006. Epub 2023 Feb 14. Exp Hematol. 2023. PMID: 36796620
Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine.
Isono N, Imai Y, Watanabe A, Moriya K, Tamura H, Inokuchi K, Asano C, Masuda M, Shimura H, Mitsuhashi K, Kazama H, Sugimori H, Motoji T, Tanaka J. Isono N, et al. Among authors: imai y. Leuk Lymphoma. 2016 Sep;57(9):2204-7. doi: 10.3109/10428194.2015.1126589. Epub 2015 Dec 24. Leuk Lymphoma. 2016. PMID: 26699798 Clinical Trial. No abstract available.
Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era.
Tsukune Y, Sasaki M, Odajima T, Isoda A, Matsumoto M, Koike M, Tamura H, Moriya K, Ito S, Asahi M, Imai Y, Tanaka J, Handa H, Koiso H, Tanosaki S, Hua J, Hagihara M, Yahata Y, Suzuki S, Watanabe S, Sugimori H, Komatsu N. Tsukune Y, et al. Among authors: imai y. Ann Hematol. 2016 Sep;95(9):1465-72. doi: 10.1007/s00277-016-2742-7. Epub 2016 Jun 30. Ann Hematol. 2016. PMID: 27358178
Clinical impact of serum soluble SLAMF7 in multiple myeloma.
Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, Tanosaki S, Ito S, Odajima T, Sugimori H, Asayama T, Sunakawa M, Kaito Y, Kinoshita R, Kuribayashi Y, Onodera A, Moriya K, Tanaka J, Tsukune Y, Komatsu N, Inokuchi K, Tamura H. Ishibashi M, et al. Among authors: imai y. Oncotarget. 2018 Oct 5;9(78):34784-34793. doi: 10.18632/oncotarget.26196. eCollection 2018 Oct 5. Oncotarget. 2018. PMID: 30410677 Free PMC article.
SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma.
Ishibashi M, Takahashi R, Tsubota A, Sasaki M, Handa H, Imai Y, Tanaka N, Tsukune Y, Tanosaki S, Ito S, Asayama T, Sunakawa M, Kaito Y, Kuribayashi-Hamada Y, Onodera A, Moriya K, Komatsu N, Tanaka J, Odajima T, Sugimori H, Inokuchi K, Tamura H. Ishibashi M, et al. Among authors: imai y. Mol Cancer Res. 2020 Apr;18(4):632-643. doi: 10.1158/1541-7786.MCR-19-0391. Epub 2020 Jan 23. Mol Cancer Res. 2020. PMID: 31974290
4,546 results